5-112827916-A-T
Variant summary
Our verdict is Benign. The variant received -13 ACMG points: 0P and 13B. BS1BS3BS2BP4
This summary comes from the ClinGen Evidence Repository: The c.1549-13A>T variant in APC is an intronic variant which is located 13 nucleotides upstream of exon 13. This variant has been observed in 10 individuals worth 10 healthy individual points (Ambry internal data). The highest population minor allele frequency in the non-cancer cohort of gnomAD v2.1.1 is 0.003915% in the non-Finnish European population, which is higher than the ClinGen APC VCEP threshold (0.001%) for BS1, and therefore meets this criterion (BS1). RT-PCR demonstrated no impact of the variant on splicing with evidence of biallelic expression (BS3, Ambry internal data). The results from ≥2 in silico splicing predictors (SpliceAI, MaxEntScan, VarSeak) support that this variant does not affect splicing (BP4). In summary, this variant is classified as Benign for autosomal dominant familial adenomatous polyposis as specified by the InSiGHT Hereditary Colorectal Cancer/Polyposis VCEP. Criteria applied: BS1, BS2, BS3, BP4 (Specification Version 1.0, date of approval: 10/12/2022). LINK:https://erepo.genome.network/evrepo/ui/classification/CA005295/MONDO:0021056/089
Frequency
Consequence
NM_000038.6 intron
Scores
Clinical Significance
Conservation
Publications
- classic or attenuated familial adenomatous polyposisInheritance: AD Classification: DEFINITIVE Submitted by: ClinGen
- desmoid tumorInheritance: AD Classification: DEFINITIVE, STRONG Submitted by: G2P, Genomics England PanelApp
- familial adenomatous polyposis 1Inheritance: AD Classification: DEFINITIVE, STRONG, MODERATE Submitted by: Genomics England PanelApp, Labcorp Genetics (formerly Invitae), Ambry Genetics
- gastric adenocarcinoma and proximal polyposis of the stomachInheritance: AD Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Ambry Genetics, Labcorp Genetics (formerly Invitae), ClinGen, Orphanet
- sarcomaInheritance: AD Classification: MODERATE Submitted by: Genomics England PanelApp
- APC-related attenuated familial adenomatous polyposisInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- Turcot syndrome with polyposisInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- Cenani-Lenz syndactyly syndromeInheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet
Genome browser will be placed here
ACMG classification
Our verdict: Benign. The variant received -13 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0000394 AC: 6AN: 152246Hom.: 0 Cov.: 32 show subpopulations
GnomAD2 exomes AF: 0.0000160 AC: 4AN: 250586 AF XY: 0.0000148 show subpopulations
GnomAD4 exome AF: 0.0000226 AC: 33AN: 1457924Hom.: 0 Cov.: 29 AF XY: 0.0000179 AC XY: 13AN XY: 725606 show subpopulations
Age Distribution
GnomAD4 genome AF: 0.0000394 AC: 6AN: 152246Hom.: 0 Cov.: 32 AF XY: 0.0000538 AC XY: 4AN XY: 74384 show subpopulations
Age Distribution
ClinVar
Submissions by phenotype
Familial adenomatous polyposis 1 Benign:3
- -
This variant is considered likely benign. This variant is intronic and is not expected to impact mRNA splicing. -
The c.1549-13A>T variant in APC is an intronic variant which is located 13 nucleotides upstream of exon 13. This variant has been observed in 10 individuals worth 10 healthy individual points (Ambry internal data). The highest population minor allele frequency in the non-cancer cohort of gnomAD v2.1.1 is 0.003915% in the non-Finnish European population, which is higher than the ClinGen APC VCEP threshold (0.001%) for BS1, and therefore meets this criterion (BS1). RT-PCR demonstrated no impact of the variant on splicing with evidence of biallelic expression (BS3, Ambry internal data). The results from more than 2 in silico splicing predictors (SpliceAI, MaxEntScan, VarSeak) support that this variant does not affect splicing (BP4). In summary, this variant is classified as Benign for autosomal dominant familial adenomatous polyposis as specified by the InSiGHT Hereditary Colorectal Cancer/Polyposis VCEP. Criteria applied: BS1, BS2, BS3, BP4 (Specification Version 1.0, date of approval: 10/12/2022). -
Hereditary cancer-predisposing syndrome Benign:2
In silico models in agreement (benign);Other data supporting benign classification -
- -
not provided Uncertain:1
- -
not specified Benign:1
This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. -
Classic or attenuated familial adenomatous polyposis Benign:1
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at